Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Curevo Vaccine closes a $110 million Series B round led by Medicxi, with new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures.
-
Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
-
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine
-
Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.
-
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...
-
-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
-
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
-
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
-
TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- The chickenpox (varicella) vaccine has markedly decreased the incidence of chickenpox. Although chickenpox is almost always a mild disease,...
-
New York, Feb. 11, 2022 (GLOBE NEWSWIRE) -- The latest research study on “Fiber Cement Siding Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Material (Portland Cement, Silica,...